Chemoradiotherapy concomitantly induces damage to tumor cells as well as the tumor vasculature [52], therefore an increase in systemic vascular damage proteins and pro-survival growth factors including bFGF and PlGF following neoadjuvant treatment is logical. The gene discussed is FGF2; the disease is neoplasm.